Immunotech Biopharm's (HKG:6978) loss attributable to owners in 2024 narrowed year on year to 186.9 million yuan or 0.36 per share from 334.8 million yuan or 0.65 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.
The biopharmaceutical company's other income surged 220% to 33.8 million yuan from 10.5 million yuan in the previous year.
No dividend was recommended for the period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。